Reality Check on Hemophilia
Market access for Hemophilia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Complex dual-benefit coverage structure with evolving medical benefit policies
- Class Trends: Anticipated product approvals may develop improved product placement based on potential cost, adherence and efficacy advantages
- Key Findings: How distinctions between human and recombinant treatment policies affect market position
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.